Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EO2463 |
Trade Name | |
Synonyms | EO 2463|EO-2463 |
Drug Descriptions |
EO2463 is a cancer vaccine comprised of microbiome-derived peptides homologous to tumor-associated antigens (TAA), which when presented by dendritic cells may lead to activation of T-cell mediated immune response against the TAAs expressed on tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C176953 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
EO2463 | EO2463 | 0 | 1 |
EO2463 + Lenalidomide + Rituximab | EO2463 Lenalidomide Rituximab | 0 | 1 |
EO2463 + Rituximab | EO2463 Rituximab | 0 | 1 |